Total trials
1,545
Active
185
Phase 3
282
Total enrollment
2,976,420
Pipeline matrix
Showing 40 of 167 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Mavacamten | — | 25 | |||||
| Luspatercept | — | — | 15 | ||||
| Xanomeline/Trospium Chloride | — | — | — | 5 | |||
| Nivolumab + Relatlimab | — | — | 5 | ||||
| BMS-986165 | — | — | 37 | ||||
| BMS-986374 | — | — | — | — | — | 1 | |
| Nivolumab | — | 204 | |||||
| Deucravacitinib | — | 29 | |||||
| KarXT | — | — | — | 14 | |||
| Carboplatin | — | — | — | 41 | |||
| Pumitamig | — | — | — | — | 10 | ||
| Ipilimumab | — | 120 | |||||
| Cisplatin | — | — | — | 28 | |||
| Pemetrexed | — | — | — | 22 | |||
| Gemcitabine | — | — | — | 16 | |||
| KarX-EC | — | — | — | — | 7 | ||
| Pembrolizumab | — | — | — | — | 6 | ||
| Ozanimod | — | — | 12 | ||||
| Paclitaxel | — | — | — | 40 | |||
| Bevacizumab | — | — | — | 12 | |||
| Nab-paclitaxel | — | — | — | 10 | |||
| BMS-986504 | — | — | — | 5 | |||
| BMS-986278 | — | — | — | 16 | |||
| Iza-bren | — | — | — | — | — | 4 | |
| Cetuximab | — | — | — | 12 | |||
| Fluorouracil | — | — | — | 8 | |||
| Capecitabine | — | — | — | 8 | |||
| Oxaliplatin | — | — | — | 6 | |||
| Cabozantinib | — | — | — | 6 | |||
| Xanomeline Enteric | — | — | — | — | 3 | ||
| Dexamethasone | — | — | 21 | ||||
| Relatlimab | — | — | 19 | ||||
| Apremilast | — | — | — | — | 5 | ||
| Oral azacitidine | — | — | — | 4 | |||
| Docetaxel | — | — | — | 18 | |||
| Leucovorin | — | — | — | 12 | |||
| Sunitinib | — | — | — | 4 | |||
| FOLFOX | — | — | — | — | 3 | ||
| BMS-986489 | — | — | — | — | 2 | ||
| Nivolumab and rHuPH20 | — | — | — | — | 2 |
127 more active programs hidden
Next readouts
- 2020-02-12
- 2020-07-17
- 2021-01-25
- 2022-06-28
- 2023-06-14
- 2023-07-26
- 2023-10-05
- 2024-02-06
- 2024-07-26
- 2024-08-22
Top conditions
- Rheumatoid Arthritis78
- Healthy Participants74
- Melanoma70
- HIV Infections68
- Healthy Volunteers55
- Hepatitis C47
- Multiple Myeloma32
- Cancer28
Frequently asked questions about Bristol-Myers Squibb
- How many clinical trials does Bristol-Myers Squibb have on ClinicalTrials.gov?
- Bristol-Myers Squibb is listed as the lead sponsor on 1,545 clinical trials in ClinicalTrials.gov, 185 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bristol-Myers Squibb's trials are in Phase 3?
- 282 of Bristol-Myers Squibb's trials are in Phase 3, spread across 167 active drug programs.
- What therapeutic areas does Bristol-Myers Squibb focus on?
- Bristol-Myers Squibb's most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Healthy Participants, Melanoma, HIV Infections, Healthy Volunteers.
- When are Bristol-Myers Squibb's next clinical trial readouts?
- Bristol-Myers Squibb has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma”, expected around 2020-02-12.